Targacept’s AstraZeneca Deal Down, Not Out
This article was originally published in The Pink Sheet Daily
Executive Summary
First Alzheimer’s Phase III results are not great, but partner wants to see more before deciding.
You may also be interested in...
Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors
Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.
Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors
Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.
Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug